Indivior 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가	UK£12.38
52주 최고가	UK£12.64
52주 최저가	UK£5.55
베타	0.26
1개월 변동	22.82%
3개월 변동	51.81%
1년 변동	25.43%
3년 변동	-22.91%
5년 변동	80.20%
IPO 이후 변동	65.07%

최근 뉴스 및 업데이트

Recent updates

분석 기사 • May 23

Indivior PLC (LON:INDV) Held Back By Insufficient Growth Even After Shares Climb 26%

Indivior PLC ( LON:INDV ) shareholders would be excited to see that the share price has had a great month, posting a...

새로운 내러티브 • May 06

SUBLOCADE Investments Will Improve Patient And Physician Experience

Commercial investments and label updates for SUBLOCADE are expected to boost revenue growth and enhance patient and physician experience.

분석 기사 • Apr 28

Results: Indivior PLC Exceeded Expectations And The Consensus Has Updated Its Estimates

A week ago, Indivior PLC ( LON:INDV ) came out with a strong set of quarterly numbers that could potentially lead to a...

분석 기사 • Feb 21

The Market Doesn't Like What It Sees From Indivior PLC's (LON:INDV) Revenues Yet As Shares Tumble 26%

Indivior PLC ( LON:INDV ) shareholders won't be pleased to see that the share price has had a very rough month...

분석 기사 • Nov 15

A Piece Of The Puzzle Missing From Indivior PLC's (LON:INDV) 35% Share Price Climb

Those holding Indivior PLC ( LON:INDV ) shares would be relieved that the share price has rebounded 35% in the last...

분석 기사 • Sep 24

Positive Sentiment Still Eludes Indivior PLC (LON:INDV) Following 26% Share Price Slump

To the annoyance of some shareholders, Indivior PLC ( LON:INDV ) shares are down a considerable 26% in the last month...

분석 기사 • Aug 09

Indivior PLC's (LON:INDV) Shares Leap 37% Yet They're Still Not Telling The Full Story

Indivior PLC ( LON:INDV ) shareholders are no doubt pleased to see that the share price has bounced 37% in the last...

분석 기사 • May 29

Indivior PLC's (LON:INDV) Shares Not Telling The Full Story

With a price-to-sales (or "P/S") ratio of 2.2x Indivior PLC ( LON:INDV ) may be sending bullish signals at the moment...

분석 기사 • May 03

Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why

Key Insights Indivior will host its Annual General Meeting on 9th of May CEO Mark Crossley's total compensation...

분석 기사 • Apr 10

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

분석 기사 • Feb 28

The Market Lifts Indivior PLC (LON:INDV) Shares 26% But It Can Do More

Indivior PLC ( LON:INDV ) shares have continued their recent momentum with a 26% gain in the last month alone. Looking...

분석 기사 • Dec 11

Are Investors Undervaluing Indivior PLC (LON:INDV) By 50%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Indivior fair value estimate is UK£23.62 Indivior is estimated...

분석 기사 • Oct 15

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

분석 기사 • Jun 27

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

분석 기사 • Mar 29

Indivior (LON:INDV) Has A Pretty Healthy Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

주주 수익률

	INDV	GB Pharmaceuticals	GB 시장
7D	3.3%	-0.03%	1.2%
1Y	25.4%	16.1%	19.4%

수익률 대 산업: INDV은 지난 1년 동안 16.1%의 수익을 기록한 UK Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.

수익률 대 시장: INDV은 지난 1년 동안 19.4%를 기록한 UK 시장보다 더 좋은 성과를 냈습니다.

주가 변동성

Is INDV's price volatile compared to industry and market?
INDV volatility
INDV Average Weekly Movement	5.6%
Pharmaceuticals Industry Average Movement	5.1%
Market Average Movement	5.2%
10% most volatile stocks in GB Market	10.5%
10% least volatile stocks in GB Market	2.7%

안정적인 주가: INDV는 지난 3개월 동안 UK 시장에 비해 주가 변동성이 크지 않았습니다.

시간에 따른 변동성: INDV의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.

회사 소개

설립	직원 수	CEO	웹사이트
2014	1,041	Joe Ciaffoni	www.indivior.com

인디비어 PLC는 자회사와 함께 미국, 유럽, 캐나다, 호주 및 전 세계에서 오피오이드 의존성 및 관련 장애 치료를 위한 부프레노르핀 기반 처방약을 개발, 제조 및 판매합니다. 이 회사는 약물 사용 장애를 치료하는 의약품을 개발합니다. 주요 시판 제품으로는 부프레노르핀 서방형 월 1회 주사제인 수블로케이드, 부프레노르핀 및 날록손 설하 필름인 수박스원 필름, 부프레노르핀 및 날록손 설하 정제인 수박스원 정제, 오피오이드 사용 장애(OUD) 치료용 부프레노르핀 설하 정제인 수부텍스 정제가 있습니다.

Indivior PLC 기초 지표 요약

Indivior의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
INDV 기초 통계
시가총액	UK£2.14b
순이익 (TTM)	-UK£46.14m
매출 (TTM)	UK£870.68m

1.8x

주가매출비율(P/S)

-33.5x

주가수익비율(P/E)

INDV는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
INDV 손익계산서 (TTM)
매출	US$1.17b
매출원가	US$215.00m
총이익	US$955.00m
기타 비용	US$1.02b
순이익	-US$62.00m

최근 보고된 실적

Mar 31, 2025

다음 실적 발표일

Jul 31, 2025

주당순이익(EPS)	-0.50
총이익률	81.62%
순이익률	-5.30%
부채/자본 비율	-115.4%

INDV의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/07/26 19:54
종가	2025/07/24 00:00
수익	2025/03/31
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Indivior Pharmaceuticals, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Glen Santangelo	Barclays
Graham Glyn Parry	BofA Global Research
Chase Knickerbocker	Craig-Hallum Capital Group LLC

This company listing is no longer active

Indivior (INDV) 주식 개요

강점

위험 분석

Analyst Price Targets

SUBLOCADE Investments Will Improve Patient And Physician Experience

Top Analyst Narratives

SUBLOCADE Investments Will Improve Patient And Physician Experience

Indivior PLC 경쟁사

HUTCHMED (China)

Hikma Pharmaceuticals

Allergy Therapeutics

Animalcare Group

가격 이력 및 성과

최근 뉴스 및 업데이트

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange

Indivior PLC Announces Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

Indivior PLC to Report Q2, 2025 Results on Jul 31, 2025

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs, Effective July 7, 2025

Indivior PLC Appoints Tony Kingsley as Independent Non-Executive Director, Effective July 1, 2025

Indivior PLC Presents New Data at CPDD Demonstrating That High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

Recent updates

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange

Indivior PLC Announces Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

Indivior PLC to Report Q2, 2025 Results on Jul 31, 2025

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs, Effective July 7, 2025

Indivior PLC Appoints Tony Kingsley as Independent Non-Executive Director, Effective July 1, 2025

Indivior PLC Presents New Data at CPDD Demonstrating That High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

Indivior Intends to Cancel LSE Listing

High number of new directors

Indivior PLC (LON:INDV) Held Back By Insufficient Growth Even After Shares Climb 26%

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through Ind Enabling Studies

SUBLOCADE Investments Will Improve Patient And Physician Experience

Results: Indivior PLC Exceeded Expectations And The Consensus Has Updated Its Estimates

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Indivior PLC, Annual General Meeting, May 08, 2025

New major risk - Negative shareholders equity

Indivior PLC Announces Appointment of Joe Ciaffoni as Chief Executive Officer

Indivior PLC Announces Board and Board Committee Changes

Independent Non-Executive Director recently bought UK£399k worth of stock

Indivior PLC Announces Stepping Down of Mark Crossley as Chief Executive Officer

Indivior Announces FDA Approval of Label Changes for SUBLOCADE (Buprenorphine Extended-Release) Injection

Indivior plc Provides Revenue Guidance for the Year 2025

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

The Market Doesn't Like What It Sees From Indivior PLC's (LON:INDV) Revenues Yet As Shares Tumble 26%

New minor risk - Share price stability

Indivior PLC Announces Delayed FDA Approval of SUBLOCADE® Label Changes

Indivior PLC to Report Q4, 2024 Results on Feb 20, 2025

Indivior PLC Appoints Daniel A. Ninivaggi to the Board as an Independent Non-Executive Director

Indivior plc Appoints David Wheadon as Chair of the Board and Chair of the Nomination Committee

High number of new directors

Independent Non-Executive Director recently bought UK£200k worth of stock

Indivior PLC Announces Ryan Preblick Steps Down as Chief Financial Officer

Indivior PLC Shares Results from a Randomized, Open-Label Sub-Study in Opioid-Dependent Participants Seeking Treatment

A Piece Of The Puzzle Missing From Indivior PLC's (LON:INDV) 35% Share Price Climb

Jerome Lande to Step Down from the Board of Indivior plc

Oaktree Capital Sends a Letter to Indivior PLC

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Indivior PLC's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the Board

Positive Sentiment Still Eludes Indivior PLC (LON:INDV) Following 26% Share Price Slump

Indivior PLC Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Moderate to Severe Cannabis Use Disorder

Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration

Indivior PLC's (LON:INDV) Shares Leap 37% Yet They're Still Not Telling The Full Story

Pomerantz Law Firm Announces the Filing of a Class Action Against Indivior PLC and Certain Officers

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,649,017 shares, for $100 million.

Consensus EPS estimates increase by 44%

Consensus EPS estimates fall by 37%

Indivior PLC Provides Revenue Guidance for the Second Quarter of 2024

Indivior PLC(LSE:INDV) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

Indivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory Depression

Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder

Indivior PLC's (LON:INDV) Shares Not Telling The Full Story

Indivior plc Reaffirms Revenue Guidance for the Year 2024

Indivior PLC Announces Board Committee Changes

Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why

Indivior plc Reconfirms Earnings Guidance for 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations